Zhi-meng Lu

发表

Polymorphisms of microsomal triglyceride transfer protein in different hepatitis B virus-infected patients.

Shen-Ying Zhang, Q. Gong, Xinxin Zhang, 2008, World journal of gastroenterology.

Expression of hepatitis C virus hypervariable region 1 and its clinical significance.

Y. Wang, Shen-Ying Zhang, Xinxin Zhang, 2003, World journal of gastroenterology.

Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy

Y. Wang, Shen-Ying Zhang, Q. Gong, 2003, Journal of gastroenterology and hepatology.

Treatment of chronic hepatitis B virus infection: An Asia–Pacific perspective

Roger Williams, G. Lau, W. Carman, 1999, Journal of gastroenterology and hepatology.

Variant analysis and immunogenicity prediction of envelope gene of HCV strains from China

Zhi-meng Lu, Lifeng Tian, Q. Cai, 2002, Journal of medical virology.

Effect of multiple mutations in the core promoter and pre‐core/core region of hepatitis B virus genome on the response to interferon in e antigen‐positive chronic hepatitis B

Xinxin Zhang, Zhenghui Luo, Zhi-meng Lu, 2001, Journal of gastroenterology and hepatology.

1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B

P. Marcellin, C. Yurdaydın, G. Lau, 2003 .

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients

Q. Gong, De-min Yu, Yue Han, 2009, Journal of gastroenterology and hepatology.

95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine

P. Marcellin, G. Lau, P. Farci, 2004 .

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

P. Marcellin, C. Yurdaydın, G. Lau, 2009, Gastroenterology.

[Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].

Xinyue Chen, H. Ren, J. Hou, 2007, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

P. Marcellin, T. Piratvisuth, H. Kapprell, 2013, Hepatology International.

683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

P. Marcellin, C. Yurdaydın, G. Lau, 2008 .

Assessment of Specific Antibodies to F Protein in Serum Samples from Chinese Hepatitis C Patients Treated with Interferon plus Ribavarin

Q. Gong, De-min Yu, Xinxin Zhang, 2008, Journal of Clinical Microbiology.

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

P. Marcellin, C. Yurdaydın, G. Lau, 2009 .

Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay.

Zhi-meng Lu, Yuan Wang, Guang-di Li, 2002, World journal of gastroenterology.

Development of the diagnostic immunoassay to detect anti-PreS1(21-47aa) antibody--a marker suggesting the health improvement of hepatitis B patients.

Xiao-jin Liu, Zhi-meng Lu, Yuan Wang, 2002, Clinica chimica acta; international journal of clinical chemistry.

Clinical and molecular characterization of Wilson's disease in China: identification of 14 novel mutations

G. Zang, Q. Gong, Yue Han, 2011, BMC Medical Genetics.

Clinical evaluation of a colorimetric oligonucleotide chip for genotyping hepatitis C virus.

Jianlong Zhao, Hongju Mao, Yong-zhong Wang, 2010, Clinical biochemistry.

Colorimetric oligonucleotide array for genotyping of hepatitis C virus based on the 5' non-coding region.

Kangdong Liu, Mengsu Yang, Jianlong Zhao, 2008, Clinica chimica acta; international journal of clinical chemistry.

Association of Genetic Variation in Il28B with Hepatitis C Treatment-Induced Viral Clearance in the Chinese Han Population

Shen-Ying Zhang, Q. Gong, Yue Han, 2011, Antiviral therapy.

Identification of a ferrochelatase mutation in a Chinese family with erythropoietic protoporphyria.

Q. Gong, Xinxin Zhang, X. Kong, 2008, Journal of hepatology.

Case report Identification of a ferrochelatase mutation in a Chinese family with erythropoietic protoporphyria q

Q. Gong, Xinxin Zhang, X. Kong, 2008 .

MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment.

Shen-Ying Zhang, Q. Gong, Yue Han, 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.

K. Luo, Zhi-meng Lu, G. Zhao, 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Clinical evaluation of a colorimetric oligonucleotide chip for genotyping hepatitis C virus.

Jianlong Zhao, Hongju Mao, Yong-zhong Wang, 2010, Clinical biochemistry.

Broadly cross‐reactive mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and screened by phage display library

Y. Wang, Shen-Ying Zhang, Xinxin Zhang, 2003, Journal of medical virology.